Products for Research Use Only
RegisterLogin

ZLY06

CAT: 0804-HY-168049-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-168049-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM) . ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis[1][2].
CAS Number
2834727-04-5
UNSPSC
12352005
Target
Akt; PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Vitamin D Related/Nuclear Receptor
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/zly06.html
Concentration
10mM
Purity
98.75
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(/C=C2OC(C=C(OCC3CC3)C=C4)=C4C\2=O)=CC(C)=C1OC(C)(C)C(O)=O
Molecular Formula
C25H26O6
Molecular Weight
422.47
References & Citations
[1]Zheng Li, et al. "Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome." European Journal of Medicinal Chemistry 225 (2021) : 113807.|[2]Xiaotong Cai, et al. "Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation." Chemical Research in Toxicology (2024) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARγ; PPARδ

Alternative Products

CatalogName
T200490-01ZLY06

Popular Products